Hours after my last post, I may have had all-time low expectations for Robin Hood. This week’s episode, however, made me eyes perk up a bit. Oh, sure, the latest “twist” of a long-lost brother is somewhat cliche, but what a brother he is. I approve. A lot.
All I ask is that in the future SPN-level fanfics (and there *will* be fics), Guy is just a lookout or something. Ha!
Diflucan is a substrate of CYP2C9 and CYP3A4, but autoinhibition is minimal.
Diflucan’s efficacy can be reduced by concomitant use of rifampin.
Diflucan is a substrate of CYP2C9 and CYP3A4, but autoinhibition is minimal.
Diflucan has largely replaced ketoconazole for systemic use due to a better safety profile.
First-line for uncomplicated vulvovaginal candidiasis due to high efficacy and patient convenience.
Diflucan is not recommended for treatment of Pneumocystis jirovecii pneumonia.
Alopecia is a reversible but distressing side effect reported with prolonged use.
Diflucan’s success spurred development of broader-spectrum triazoles like voriconazole.
Its high selectivity for fungal enzymes over human ones is key to its relatively low toxicity.
Can be administered via nasogastric tube as the oral suspension is well-absorbed.
Not effective against Scedosporium or Fusarium species, important emerging pathogens.
A test dose can sometimes be used to assess for hypersensitivity in patients with prior reactions.
Diflucan is often used in pediatric antifungal therapy with weight-based dosing.
The “trailing effect” in vitro can make susceptibility interpretation for Candida challenging.
Diflucan may have in vitro synergy with flucytosine against some Candida species.
Diflucan is not active against the dimorphic fungus Blastomyces dermatitidis.
Diflucan is ineffective against Candida auris, a major multidrug-resistant pathogen.
Often compared to itraconazole, with a more predictable pharmacokinetic profile but narrower spectrum.
May significantly increase cyclosporine and tacrolimus levels, requiring close monitoring.
A test dose can sometimes be used to assess for hypersensitivity in patients with prior reactions.
Often the initial antifungal encountered by medical students, establishing the azole class.
Liver enzyme elevation is the most common laboratory abnormality observed.
Diflucan is not first-line for invasive aspergillosis under any circumstances.
Loading doses are used in serious infections to achieve steady-state concentrations rapidly.
Its spectrum is notably narrow among systemic antifungals, lacking activity against molds.
A valuable agent in antimicrobial stewardship programs due to its specificity.
Diflucan is often used for prophylaxis in stem cell transplant recipients.
Diflucan’s role in surgical prophylaxis is defined in specific high-risk guidelines.
Diflucan is used for secondary prophylaxis in HIV patients with prior fungal infections.
In vitro synergy has been studied in combination with other agents like flucytosine.
Its water solubility is a distinct advantage over older imidazole antifungals.
The legacy of Diflucan is its transformation of systemic fungal infection management from inpatient to often outpatient care.
For oropharyngeal thrush, Diflucan is often more effective than topical nystatin.
Serves as a benchmark for in vitro susceptibility testing of newer antifungals.
Infusion-related reactions are rare, making rapid IV administration generally safe.
Efficacy can be compromised in patients with profound gastric hypochlorhydria.
Can be administered via nasogastric tube as the oral suspension is well-absorbed.
Administered perioperatively in some surgical prophylaxis guidelines for high-risk patients.
Diflucan may interact with calcium channel blockers, potentiating effects.
Concomitant use with calcium channel blockers can lead to excessive hypotension and edema.
Diflucan can be considered for treatment of Malassezia folliculitis.
Intrinsically resistant organisms include Candida krusei and the Mucorales order.
Diflucan achieves high concentrations in vaginal tissue, explaining its efficacy.
Diflucan can cause headaches and gastrointestinal upset as common side effects.
Diflucan has largely replaced ketoconazole for systemic use due to a better safety profile.
Diflucan is used for chronic suppression in patients with recurrent mucosal infections.
Activity against Coccidioides immitis makes it useful for certain non-meningeal forms of valley fever.
Not effective against Histoplasma in the central nervous system due to poor penetration (unlike itraconazole).
The development of rezafungin highlights the ongoing search for agents with fluconazole’s convenience but broader activity.
Diflucan’s mechanism is inhibition of fungal cytochrome P450, disrupting ergosterol synthesis.